Pfizer and Protalix BioTherapeutics have announced FDA approval of Elelyso (taliglucerase alfa) for injection to treat type 1 Gaucher disease. Elelyso, derived from ProCellEx, is an enzyme replacement therapy (ERT) for the long-term ...
Tags: Protalix/Pfizer Gaucher Drug, Pfizer and Protalix BioTherapeutics